US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

CNS/Neurology: market research reports

RSS Feeds

CNS/Neurology market research reports and industry analysis

1  2    4    6  7  8  9  10  
Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Chronic Subdural Hematoma Global Clinical Trials Review, H1, 2014
6/20/2014 | published by: GlobalData
... report provides elemental information and data relating to the clinical trials on Chronic Subdural Hematoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across ...  |  read more...
USD 2,500
Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as ...  |  read more...
USD 3,495
Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
General Anxiety Disorder - Pipeline Review, H1 2014
5/30/2014 | published by: Global Markets Direct
... information on the therapeutic development for General Anxiety Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest ...  |  read more...
USD 2,000
Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2014
5/30/2014 | published by: Global Markets Direct
... report provides comprehensive information on the therapeutic development for Cerebral Infarction (Brain Infarction), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule ...  |  read more...
USD 2,000
Brain Injury - Pipeline Review, H1 2014
6/15/2014 | published by: Global Markets Direct
... therapeutic development for Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Cognitive Impairment Global Clinical Trials Review, H1, 2014
6/20/2014 | published by: GlobalData
... information and data relating to the clinical trials on Cognitive Impairment. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook ...  |  read more...
USD 2,500
Drug Addiction Global Clinical Trials Review, H1, 2014
6/20/2014 | published by: GlobalData
... information and data relating to the clinical trials on Drug Addiction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook ...  |  read more...
USD 2,500
Radical Innovations Based on Brain Computer Interface(BCI) (Technical Insights)
6/30/2014 | published by: Frost & Sullivan
... signals various parameters such as concentration levels, focus, and thoughts can be deciphered. These signals can then be used as input for controlling various kinds of devices. BCI is currently largely used in the healthcare ...  |  read more...
USD 6,500
Seizures - Pipeline Review, H1 2014
6/25/2014 | published by: Global Markets Direct
... Seizures, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It ...  |  read more...
USD 2,000
OpportunityAnalyzer: Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2018
6/20/2014 | published by: GlobalData
... motor neurons. ALS affects both the upper (brain to spinal cord) and lower (brain stem to muscle tissue) motor neurons, gradually reducing a patient’s ability to initiate and control muscle movement. Muscle atrophy, starting in ...  |  read more...
USD 5,995
Age Related Memory Impairment Global Clinical Trials Review, H1, 2014
5/30/2014 | published by: GlobalData
... trial scenario. This report provides elemental information and data relating to the clinical trials on Age Related Memory Impairment. It includes an overview of the trial numbers and their recruitment status as per the site ...  |  read more...
USD 2,500
Market Highlights: Spain Schizophrenia – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, schizophrenia drugs market share, schizophrenia drugs sales estimates, schizophrenia drugs sales forecast, and schizophrenia late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: France Schizophrenia – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, schizophrenia drugs market share, schizophrenia drugs sales estimates, schizophrenia drugs sales forecast, and schizophrenia late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022
2/28/2014 | published by: GlobalData
... fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the ...  |  read more...
USD 3,495
Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022
2/28/2014 | published by: GlobalData
... fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the ...  |  read more...
USD 3,495
Geodon (Schizophrenia) - Forecast and Market Analysis to 2022
2/28/2014 | published by: GlobalData
... fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the ...  |  read more...
USD 3,495
Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022
2/28/2014 | published by: GlobalData
... fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the ...  |  read more...
USD 3,495
Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022
2/28/2014 | published by: GlobalData
... fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the ...  |  read more...
USD 3,495
1  2    4    6  7  8  9  10